Approvedregulatory verdict

Evidence outlook

Approved: Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration, Diabetic Macular Edema

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
US
  • Retinopathy of Prematurity (ROP)Outside this platform's coverageFDA label
  • Macular Edema Following Retinal Vein Occlusion (RVO)Outside this platform's coverageFDA label
  • Diabetic retinopathy (DR)FDA label
Product first approved 2011
EU
  • Eylea 114.3 mg/ml solution for injection and Eylea 114.3 mg/ml solution for injection in pre-filled syringe Eylea is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) visual impairment due to diabetic macular oedema (DME) visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO) Eylea 40 mg/mL solution for injection in pre-filled syringe Eylea is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) visual impairment due to macular oedema...
Product first approved 2012EMA
JP
  • Treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization
Product first approved 2012PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (49)
Age-Related Macular Degeneration
NCT02157077 · Centre Hospitalier Intercommunal Creteil
2013-12 – 2015-12 · Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
What this study did
NCT01482910 · Bayer
2011-12 – 2014-08 · Macular Degeneration
What this study did
Diabetic Macular Edema
NCT06422507 · Bayer
2024-05-29 – 2026-03-25 · Diabetic Macular Edema
What this study did
NCT02634333 · Jaeb Center for Health Research
2016-01 – 2022-05-11 · Diabetic Retinopathy, Diabetic Macular Edema
What this study did
NCT03321513 · Jaeb Center for Health Research
2017-12-07 – 2021-12-22 · Diabetic Macular Edema
What this study did
NCT02818998 · Bayer
2016-11-16 – 2019-09-24 · Macular Edema
What this study did
NCT01627249 · Jaeb Center for Health Research
2012-08 – 2019-04-18 · Diabetic Macular Edema
What this study did
NCT01909791 · Jaeb Center for Health Research
2013-10 – 2018-09-11 · Diabetic Macular Edema
What this study did
NCT04288232 · Taipei Veterans General Hospital, Taiwan
2015-08-31 – 2017-11-16 · Center-involved Diabetic Macular Edema
What this study did
NCT01783886 · Bayer
2013-02 – 2015-03 · Macular Edema
What this study did
NCT01512966 · Bayer
2012-01 – 2013-09 · Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT06223958 · Ocular Therapeutix, Inc.
2024-01-29 – 2027-09-27 · Neovascular Age-Related Macular Degeneration
What this study did
NCT04757636 · Opthea Limited
2021-03-12 – 2025-03-31 · Neovascular Age-related Macular Degeneration
What this study did
NCT05989126 · Regeneron Pharmaceuticals
2024-04-15 – 2024-05-31 · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
What this study did
NCT04113538 · Michel Giunta
2019-07-24 – 2023-05 · Wet Age-related Macular Degeneration
What this study did
NCT05345236 · Qilu Pharmaceutical Co., Ltd.
2019-08-19 – 2022-01-25 · Wet Age-related Macular Degeneration
What this study did
NCT02540954 · Bayer
2015-09-29 – 2020-06-04 · Macular Degeneration
What this study did
NCT03386474 · Novartis Pharmaceuticals
2018-01-15 – 2018-09-06 · Neovascular Age-related Macular Degeneration
What this study did
NCT00964795 · Regeneron Pharmaceuticals
2009-12 – 2013-08 · Neovascular Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT04015180 · Bayer
2020-03-18 – 2025-09-19 · Retinopathy of Prematurity (ROP)
What this study did
NCT03845049 · Centre Hospitalier Universitaire Dijon
2019-07-03 – 2025-03-26 · Macular Telangiectasia
What this study did
NCT03172299 · Centre Hospitalier Universitaire de Nice
2017-06-08 – 2025-01-31 · Ocular Melanoma
What this study did
NCT05155293 · Alvotech Swiss AG
2022-06-28 – 2024-09-23 · Neovascular (Wet) AMD
What this study did
NCT04392479 · Hôpital Franco-Britannique-Fondation Cognacq-Jay
2020-09-02 – 2024-06 · Cancer Colorectal, Metastasis
What this study did
NCT05704725 · Amgen
2023-01-23 – 2023-03-24 · Chorioretinal Vascular Disease
What this study did
NCT04101721 · Regeneron Pharmaceuticals
2019-10-30 – 2022-08-18 · Retinopathy of Prematurity
What this study did
NCT01969708 · The Emmes Company, LLC
2014-09 – 2021-03 · Central Retinal Vein Occlusion
What this study did
NCT04004208 · Bayer
2019-09-25 – 2021-02-12 · Retinopathy of Prematurity (ROP)
What this study did
NCT02718326 · Regeneron Pharmaceuticals
2016-03-29 – 2019-07-16 · Nonproliferative Diabetic Retinopathy
What this study did
NCT02980874 · Clearside Biomedical, Inc.
2017-01-31 – 2018-12-10 · Macular Edema, Retinal Vein Occlusion
What this study did
NCT01571284 · Sanofi
2012-05-30 – 2017-01-31 · Colorectal Cancer Metastatic
What this study did
NCT02396316 · Bayer
2015-04-02 – 2016-09-06 · Glaucoma, Neovascular
What this study did
NCT02641457 · Instituto de Olhos de Goiania
2014-03 – 2015-10 · Glaucoma, Rubeosis Iridis
What this study did
NCT01661270 · Sanofi
2012-07 – 2015-07 · Colorectal Cancer Metastatic
What this study did
NCT01670721 · Sanofi
2012-08 – 2015-06 · Colorectal Cancer Metastatic
What this study did
NCT01521559 · Regeneron Pharmaceuticals
2012-04 – 2014-03 · Branch Retinal Vein Occlusion
What this study did
NCT01249664 · Bayer
2010-12 – 2013-08 · Myopia, Pathological
What this study did
NCT00943072 · Regeneron Pharmaceuticals
2009-07 – 2012-04 · Macular Edema Secondary to Central Retinal Vein Occlusion
What this study did
NCT00519285 · Sanofi
2007-08 – 2012-04 · Prostatic Neoplasms, Neoplasm Metastasis
What this study did
NCT01012973 · Bayer
2009-10 – 2012-02 · Retinal Vein Occlusion
What this study did
NCT00532155 · Sanofi
2007-09 – 2011-10 · Carcinoma, Non Small Cell Lung
What this study did
NCT00574275 · Sanofi
2007-12 – 2010-11 · Pancreatic Neoplasm
What this study did
Phase 2/3 (6)
Age-Related Macular Degeneration
NCT02296567 · East Florida Eye Institute
2014-12 – 2016-07 · Age Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT03143192 · Keyvan Koushan
2017-03-08 – 2019-05-09 · Diabetic Macular Edema
What this study did
Other / comorbidity
NCT02858076 · Jaeb Center for Health Research
2016-11 – 2020-01 · Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
What this study did
NCT01646554 · European Organisation for Research and Treatment of Cancer - EORTC
2012-12 – 2016-12 · Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer
What this study did
NCT01813773 · Ophthalmic Consultants of Long Island
2013-03 – 2016-04 · Proliferative Diabetic Retinopathy
What this study did
NCT00327444 · Sanofi
2006-07 – 2009-10 · Ovarian Neoplasms, Ascites
What this study did
Phase 2 (83)
Age-Related Macular Degeneration
NCT03452527 · Iconic Therapeutics, Inc.
2018-03-26 – 2019-04-25 · Choroidal Neovascularization, Wet Macular Degeneration
What this study did
NCT02387957 · Ophthotech Corporation
2016-04-26 – 2017-01 · Age-Related Macular Degeneration
What this study did
NCT02401945 · Santen Inc.
2015-04 – 2016-10-31 · Age-Related Macular Degeneration
What this study did
NCT01414153 · Lpath, Inc.
2012-08 – 2015-06 · Exudative Age-related Macular Degeneration
What this study did
NCT00527423 · Regeneron Pharmaceuticals
2007-08 – 2011-10 · Macular Degeneration
What this study did
Diabetic Macular Edema
NCT04418427 · Adverum Biotechnologies, Inc.
2020-05-28 – 2023-06-14 · Diabetic Macular Edema, Diabetic Retinopathy
What this study did
NCT04588948 · Stanford University
2020-12 – 2021-12 · Diabetic Macular Edema
What this study did
NCT03629210 · Pradeepa Yoganathan
2019-09 – 2021-05 · Diabetic Macular Edema
What this study did
NCT03920878 · Emory University
2020-05 – 2020-06 · Diabetic Macular Edema, Cataract
What this study did
NCT03126786 · Clearside Biomedical, Inc.
2017-07-11 – 2018-04-17 · Diabetic Macular Edema
What this study did
NCT02363621 · Arshad Khanani
2015-01 – 2017-10 · Diabetic Macular Edema
What this study did
NCT02712008 · Regeneron Pharmaceuticals
2016-03-02 – 2017-07-10 · Diabetic Macular Edema
What this study did
NCT00789477 · Regeneron Pharmaceuticals
2008-12 – 2010-09 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT04200248 · Ribomic USA Inc
2019-12-02 – 2021-12-22 · Exudative Age-related Macular Degeneration
What this study did
NCT04126317 · Regeneron Pharmaceuticals
2019-11-04 – 2021-11-30 · Neovascular (Wet) Age-Related Macular Degeneration
What this study did
NCT03423823 · Kapil Kapoor
2017-07-07 – 2020-06-26 · Wet Macular Degeneration, Wet Age-related Macular Degeneration
What this study did
NCT02462889 · Jeffrey S Heier
2015-06 – 2019-03 · Age-Related Macular Degeneration
What this study did
NCT05571267 · IVERIC bio, Inc.
2016-10-20 – 2018-04-24 · Neovascular Age-Related Macular Degeneration
What this study did
NCT02713204 · Regeneron Pharmaceuticals
2016-03-31 – 2017-10-03 · Neovascular Age-Related Macular Degeneration
What this study did
NCT02418754 · Regeneron Pharmaceuticals
2015-05-05 – 2017-04-03 · Neovascular Age-Related Macular Degeneration
What this study did
Other / comorbidity
NCT07891182 · University of Miami
2026-12 – 2028-06 · Glaucoma
What this study did
NCT04311606 · Massachusetts Eye and Ear Infirmary
2020-11-02 – 2024-12-17 · Thyroid Eye Disease
What this study did
NCT03530267 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2018-09-28 – 2024-02-01 · Colorectal Cancer
What this study did
NCT04580147 · M. Ali Khan, MD
2020-10-15 – 2023-12-15 · Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
What this study did
NCT03712904 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2019-08-09 – 2022-12-23 · Uveal Melanoma
What this study did
NCT01652196 · John Hays
2012-11-14 – 2022-08-30 · Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
What this study did
NCT03043729 · AIO-Studien-gGmbH
2017-03-06 – 2022-06-01 · Rectal Cancer, Rectosigmoid Cancer
What this study did
NCT03085784 · Amy C Schefler, MD
2017-07-05 – 2021-10 · Radiation Retinopathy
What this study did
NCT02384759 · Federation Francophone de Cancerologie Digestive
2015-05 – 2021-06 · Colorectal Neoplasms
What this study did
NCT03531294 · Greater Houston Retina Research
2018-05-23 – 2021-04-09 · Diabetic Retinopathy
What this study did
NCT02331927 · University of Ulm
2015-03 – 2021-03 · Metastatic Colorectal Cancer
What this study did
NCT02586727 · Larkin Community Hospital
2015-10 – 2020-08 · Adverse Effect of Radiation Therapy
What this study did
NCT02151695 · Poitiers University Hospital
2015-05 – 2020-03-06 · Naive Patients With Uncomplicated Proliferative Diabetic Retinopathy
What this study did
NCT02340949 · Grupo Espanol Multidisciplinario del Cancer Digestivo
2015-01 – 2020-02-04 · Rectal Cancer
What this study did
NCT03374670 · Ophthotech Corporation
2018-11 – 2019-12 · Idiopathic Polypoidal Choroidal Vasculopathy
What this study did
NCT02173990 · Centre Oscar Lambret
2014-07 – 2019-10-22 · Metastatic Colorectal Cancer
What this study did
NCT02556229 · Hospices Civils de Lyon
2016-06 – 2019-09 · Inflammatory Choroidal Neovascularization
What this study did
NCT02257502 · Hospices Civils de Lyon
2015-07-06 – 2019-07-11 · Idiopathic Choroidal Neovascularization
What this study did
NCT02863354 · Charles C Wykoff, PhD, MD
2016-08 – 2019-05 · Proliferative Diabetic Retinopathy
What this study did
NCT02624726 · Hellenic Oncology Research Group
2016-01 – 2019-03 · Metastatic Colorectal Cancer
What this study did
NCT02970916 · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
2016-11 – 2018-12 · Metastatic Colorectal Cancer
What this study did
NCT03006081 · Asan Medical Center
2016-04-14 – 2018-08-30 · Diabetic Retinopathy
What this study did
NCT02537054 · University Hospital, Bonn
2015-09 – 2018-07-02 · Pseudoxanthoma Elasticum
What this study did
NCT02573038 · Hospices Civils de Lyon
2016-02 – 2018-05 · Choroidal Neovascularization in Angioid Streaks
What this study did
NCT01258855 · National Cancer Institute (NCI)
2011-01-18 – 2018-03-29 · Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT02235324 · University of Southern California
2015-03 – 2018-03 · Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
What this study did
NCT02101918 · National Cancer Institute (NCI)
2014-06-18 – 2018-01-31 · Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma
What this study did
NCT02661711 · Moorfields Eye Hospital NHS Foundation Trust
2016-03 – 2017-10 · Macular Oedema, Retinitis Pigmentosa
What this study did
Phase 1/2 (15)
Age-Related Macular Degeneration
NCT02118831 · California Retina Consultants
2012-03 – 2014-04 · Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
What this study did
Diabetic Macular Edema
NCT02949024 · Clearside Biomedical, Inc.
2016-11-10 – 2017-10-17 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT04626128 · Clearside Biomedical, Inc.
2020-12-15 – 2022-10-13 · Neovascular Age-related Macular Degeneration
What this study did
NCT03594461 · Vitreous -Retina- Macula Consultants of New York
2018-09-11 – 2020-06 · Neovascular Age-Related Macular Degeneration
What this study did
NCT01926977 · Arshad Khanani
2013-09 – 2014-05 · Neovascular Age-Related Macular Degeneration
What this study did
Other / comorbidity
NCT01988246 · Rishi Singh
2013-12 – 2020-01-14 · Diabetic Retinopathy
What this study did
NCT02797704 · Rabin Medical Center
2017-03-02 – 2019-09-10 · Corneal Neovascularization
What this study did
NCT02976012 · Southeast Retina Center, Georgia
2016-06 – 2018-06 · Proliferative Diabetic Retinopathy
What this study did
NCT01661972 · John Strickler, M.D.
2012-08 – 2016-06-12 · Metastatic Colorectal Cancer
What this study did
NCT01724554 · Ophthalmic Consultants of Boston
2012-11 – 2014-10 · Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
What this study did
NCT01790893 · John Kitchens, MD
2013-03 – 2014-08 · Ocular Histoplasmosis
What this study did
NCT00436501 · National Cancer Institute (NCI)
2007-01 – 2012-11 · Fallopian Tube Cancer, Malignant Tumor of Peritoneum, Recurrent Ovarian Epithelial Cancer
What this study did
NCT00794417 · Regeneron Pharmaceuticals
2008-11-30 – 2011-06-30 · Advanced Carcinoma, Non-small Cell Lung Cancer
What this study did
Phase 1 (34)
Age-Related Macular Degeneration
NCT00383370 · Regeneron Pharmaceuticals
2006-10 – 2008-07 · Neovascular Age Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT06205979 · Sohag University
2023-12-12 – 2024-06-14 · Diabetic Macular Edema
What this study did
NCT00320814 · Regeneron Pharmaceuticals
2006-04 – 2007-08 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT03630315 · Ocular Therapeutix, Inc.
2019-02-18 – 2024-01-10 · Neovascular Age-related Macular Degeneration
What this study did
NCT04989699 · Ocular Therapeutix, Inc.
2021-07-28 – 2023-12-18 · Neovascular Age-Related Macular Degeneration
What this study did
NCT03585556 · Janssen Research & Development, LLC
2018-09-13 – 2022-01-18 · Wet Age-related Macular Degeneration
What this study did
NCT02204683 · University of Nebraska
2014-09-05 – 2016-12-14 · Neovascular Macular Degeneration
What this study did
NCT01997164 · Regeneron Pharmaceuticals
2014-11 – 2015-10 · Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
What this study did
NCT00320775 · Regeneron Pharmaceuticals
2005-06 – 2008-08 · Macular Degeneration
What this study did
Other / comorbidity
NCT02298959 · National Cancer Institute (NCI)
2015-04-08 – 2027-01-20 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Renal Cell Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Sarcoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT02159989 · National Cancer Institute (NCI)
2014-06-18 – 2024-01-29 · Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
What this study did
NCT02403128 · Kamal Kishore, MD
2015-05-14 – 2020-02 · Macular Edema, Retinal Artery Macroaneurysm
What this study did
NCT03396861 · Tufts Medical Center
2019-02-22 – 2020-01-02 · Irvine-Gass Syndrome
What this study did
NCT03766425 · Medical University of Lublin
2017-06-14 – 2019-07-31 · Eye Diseases, Optic Nerve Damage, Glaucoma Surgery
What this study did
NCT01579760 · Washington University School of Medicine
2012-11 – 2019-03-27 · Radiation Retinopathy, Macular Edema
What this study did
NCT01843725 · Jules Bordet Institute
2013-09 – 2016-10 · Metastatic Colorectal Cancers, Metastatic Gastric Cancers, Metastatic Oesophageal Cancers, Metastatic Pancreatic Cancers, Metastatic Biliary Cancers, Metastatic Breast Cancers
What this study did
NCT02192541 · National Cancer Institute (NCI)
2014-12-02 – 2016-02-25 · Neoplasms
What this study did
NCT01868360 · Balamurali Ambati
2013-06 – 2015-10 · Corneal Neovascularization
What this study did
NCT01578720 · Retina Research Institute, LLC
2012-06 – 2015-03 · Choroidal Neovascularization, Presumed Ocular Histoplasmosis
What this study did
NCT01688960 · Regeneron Pharmaceuticals
2012-10 – 2014-11 · Solid Tumors
What this study did
NCT00650923 · National Cancer Institute (NCI)
2008-07 – 2013-12 · Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor
What this study did
NCT00545246 · Sanofi
2007-10 – 2012-07 · Neoplasms
What this study did
NCT00921661 · Sanofi
2009-06 – 2012-06 · Colorectal Neoplasms, Neoplasm Metastasis
What this study did
NCT01148615 · Sanofi
2010-07 – 2011-12 · Neoplasm Malignant
What this study did
NCT00644124 · Sanofi
2008-03 – 2011-10 · Lymphoma, Non-Hodgkin
What this study did
NCT00479076 · Sanofi
2007-03 – 2011-01 · Neoplasms
What this study did
NCT00876044 · Sanofi
2009-04 – 2010-11 · Cancer
What this study did
NCT00622414 · National Cancer Institute (NCI)
2008-04 – 2010-02 · Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
NCT00082823 · Regeneron Pharmaceuticals
2004-01 – 2008-05 · Cancer
What this study did
NCT00083213 · Regeneron Pharmaceuticals
2004-01 – 2008-05 · Cancer
What this study did
NCT00045266 · Regeneron Pharmaceuticals
2002-04 – 2007-02 · Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00036946 · Regeneron Pharmaceuticals
2001-11 – 2002-03 · Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
Phase 4 (91)
Age-Related Macular Degeneration
NCT07940998 · Honghua Yu,MD
2026-11-15 – 2028-09-30 · Agerelated Macular Degeneration
What this study did
NCT07365371 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2026-01-01 – 2027-12-31 · Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
What this study did
NCT06683950 · Kim's Eye Hospital
2024-10-21 – 2026-07-14 · Age-related Macular Degeneration (ARMD)
What this study did
NCT03056079 · Unity Health Toronto
2017-02-28 – 2024-02-28 · Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Macular Edema
What this study did
NCT02681783 · Sunnybrook Health Sciences Centre
2018-12-01 – 2022-12-01 · Central Serous Chorioretinopathy, Age Related Macular Degeneration, Idiopathic Poplypoidal Choroidal Vasculopathy
What this study did
NCT03117634 · Singapore National Eye Centre
2017-12-01 – 2021-01-31 · Age Related Macular Degeneration, Polypoidal Choroidal Vasculopathy
What this study did
NCT03022292 · University of California, Los Angeles
2017-03-30 – 2020-08-31 · Wet Macular Degeneration
What this study did
NCT02689518 · University of California, San Diego
2014-04 – 2019-11-12 · Macular Degeneration, Wet Macular Degeneration
What this study did
NCT03169660 · Kim's Eye Hospital
2015-12 – 2019-01-20 · Exudative Age-related Macular Degeneration
What this study did
NCT03804099 · Augenabteilung Allgemeines Krankenhaus Linz
2017-03-01 – 2018-05-18 · Macular Degeneration, Anti Vascular Endothelial Growth Factor
What this study did
NCT01657669 · Retina Research Institute, LLC
2012-10 – 2017-12 · Age Related Macular Degeneration
What this study did
NCT02120950 · Bayer
2014-05-29 – 2017-07-07 · Neovascular Macular Degeneration
What this study did
NCT01961414 · Palmetto Retina Center, LLC
2013-10 – 2016-07 · Exudative Age-related Macular Degeneration
What this study did
NCT01670162 · Tennessee Retina
2012-08 – 2016-01 · Age Related Macular Degeneration, Pigment Epithelial Detachment
What this study did
NCT01617148 · Rishi Singh
2012-06 – 2015-12 · Exudative Macular Degeneration
What this study did
NCT01950741 · Pusan National University Hospital
2013-09 – 2015-08 · Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
What this study did
NCT01824225 · Nihon University
2013-03 – 2015-03 · Age-related Macular Degeneration
What this study did
NCT01543568 · David M. Brown, M.D.
2012-02 – 2014-10 · Age Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT07612904 · The Third Peoples Hospital of Dalian
2026-06-30 – 2028-07-31 · Diabetic Macular Edema (DME)
What this study did
NCT07301775 · Ahmad Zeeshan Jamil
2026-01-01 – 2026-09-30 · Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract, Phacoemulfisication+IOL Implantation, Intravitreal Injection
What this study did
NCT04411693 · The Cleveland Clinic
2020-04-10 – 2025-05-14 · Diabetic Macular Edema
What this study did
NCT07924072 · Benha University
2024-01-01 – 2025-01-01 · Diabetic Macular Edema
What this study did
NCT04469595 · Alimera Sciences
2020-08-31 – 2024-12-31 · Diabetic Macular Edema
What this study did
NCT03780361 · Hyewon Chung
2019-05-17 – 2024-02-01 · Diabetic Macular Edema
What this study did
NCT03197480 · Singapore National Eye Centre
2019-04-17 – 2021-03-01 · Diabetic Macular Edema
What this study did
NCT02559180 · Rishi Singh
2015-10 – 2020-12 · Diabetic Retinopathy, Macular Edema
What this study did
NCT03059277 · Southeast Clinical Research Associates, LLC
2018-06-01 – 2020-09-30 · Diabetic Macular Edema
What this study did
NCT02788877 · Pusan National University Hospital
2016-04-10 – 2019-12 · Macular Edema, Diabetic
What this study did
NCT02441907 · Unity Health Toronto
2015-08 – 2019-09 · Diabetic Macular Edema
What this study did
NCT04087746 · Minia University
2017-01 – 2019-06 · Diabetic Macular Edema
What this study did
NCT03866746 · Al Hadi Hospital
2017-05-08 – 2018-12-28 · Diabetic Macular Edema
What this study did
NCT02392364 · California Retina Consultants
2015-04-15 – 2018-11-15 · Cystoid Macular Edema, Diabetic Macular Edema
What this study did
NCT02471651 · California Retina Consultants
2015-06 – 2018-10-24 · Diabetic Macular Edema
What this study did
NCT02633852 · Hadassah Medical Organization
2016-05-24 – 2018-09-06 · Diabetic Macular Edema (DME)
What this study did
NCT03453281 · Universitas Indonesia
2017-10-10 – 2018-05-18 · Diabetic Macular Edema, Diabetic Retinopathy, Clinically Significant Macular Edema
What this study did
NCT02297204 · Northern California Retina Vitreous Associates
2014-11 – 2018-03-19 · Diabetic Macular Edema
What this study did
NCT02503540 · Justis Ehlers
2015-08-18 – 2018-02-06 · Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
What this study did
NCT02924987 · Maisonneuve-Rosemont Hospital
2016-11 – 2017-11 · Diabetic Macular Edema
What this study did
NCT02734407 · Retina-Vitreous Associates Medical Group
2015-01 – 2017-09-27 · Clinically Significant Diabetic Macular Edema
What this study did
NCT02878681 · Novartis Pharmaceuticals
2016-09 – 2017-09 · Visual Impairment Due to Diabetic Macular Edema
What this study did
NCT02299336 · Greater Houston Retina Research
2014-11-24 – 2017-01-09 · Diabetic Macular Edema
What this study did
NCT02258009 · Novartis Pharmaceuticals
2015-10 – 2016-10 · Visual Impairment Due to Diabetic Macular Edema
What this study did
NCT02646670 · Instituto de Olhos de Goiania
2015-07 – 2015-11 · Retinal Diseases
What this study did
Wet Age-Related Macular Degeneration
NCT06591598 · Bayer
2024-09-02 – 2025-10-14 · Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
What this study did
NCT06330220 · Seoul National University Hospital
2021-02-10 – 2022-02-28 · Age-Related Macular Degeneration
What this study did
NCT03468296 · Tennessee Retina
2018-04 – 2019-07 · Neovascular Age-related Macular Degeneration
What this study did
Early phase / not applicable (31)
Age-Related Macular Degeneration
NCT06929507 · University Hospital, Alexandroupolis
2025-03-10 – 2027-03-10 · Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
What this study did
NCT02174211 · King's College Hospital NHS Trust
2014-06 – 2020-12 · Age Related Macular Degeneration
What this study did
NCT03038048 · Wills Eye
2017-01-27 – 2017-04-27 · Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
What this study did
NCT01746875 · Norwegian University of Science and Technology
2014-02 – 2015-09 · Macular Degeneration, Retinal Detachment
What this study did
NCT01640171 · Retina Vitreous Associates of Florida
2012-07 – 2013-10 · Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
What this study did
Diabetic Macular Edema
NCT02645266 · McMaster University
2018-05-01 – 2027-12 · Diabetic Macular Edema
What this study did
NCT07338097 · CMH Multan Institute of Medical Sciences
2025-09-07 – 2026-02-07 · Diabetic Macular Edema (DME)
What this study did
NCT05731089 · Al Hadi Hospital
2019-09-01 – 2022-12-01 · Diabetic Macular Edema
What this study did
NCT04856397 · Uptown Eye Specialists
2021-05-25 – 2021-12-29 · Diabetic Macular Edema
What this study did
NCT04014556 · University of Alexandria
2016-04-01 – 2018-12-01 · Diabetic Macular Edema
What this study did
NCT02554747 · Odense University Hospital
2015-10 – 2018-11 · Diabetic Macular Oedema
What this study did
NCT03974425 · University of Alexandria
2016-04-01 – 2018-04-01 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT04932980 · Berner Augenklinik
2022-05-09 – 2028-03 · Wet Age-related Macular Degeneration
What this study did
NCT03509623 · University Hospital of Patras
2017-08-02 – 2018-04-27 · Neovascular Age-related Macular Degeneration
What this study did
NCT02457026 · Duke University
2016-01 – 2018-01 · Neovascular Age-related Macular Degeneration
What this study did
NCT01773954 · MidAtlantic Retina
2013-02 – 2016-03 · Age-Related Macular Degeneration, Macular Degeneration
What this study did
Other / comorbidity
NCT04793100 · Fondation Ophtalmologique Adolphe de Rothschild
2021-03-24 – 2025-03-17 · Central Retinal Vein Occlusion
What this study did
NCT03941587 · Singapore National Eye Centre
2021-02-01 – 2024-06-06 · Polypoidal Choroidal Vasculopathy
What this study did
NCT04707027 · Chiang Mai University
2020-11-01 – 2023-11 · Polypoidal Choroidal Vasculopathy
What this study did
NCT06146309 · Al-Azhar University
2020-12-01 – 2022-08-01 · Branch Retinal Vein Occlusion
What this study did
NCT04882956 · Benha University
2020-08-05 – 2022-03 · Macula Lutea Degeneration
What this study did
NCT03651011 · Odense University Hospital
2018-08-10 – 2021-10-05 · Branch Retinal Vein Occlusion, Macular Edema
What this study did
NCT03908723 · Alexandria University
2019-03-29 – 2021-05-29 · Macular Edema Caused by Leber's Miliary Aneurysms
What this study did
NCT04970251 · Siriraj Hospital
2018-11-01 – 2021-03-31 · Intraocular Pressure, Neovascular Glaucoma, Vascular Endothelial Growth Factor Overexpression, Glaucoma Secondary to Eye Inflammation
What this study did
NCT04252456 · Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
2018-04-23 – 2021-02 · Advanced Colorectal Cancer
What this study did
NCT04075188 · Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
2017-09-18 – 2019-07-13 · Choroidal Neovascularization, Choroid Disease
What this study did
NCT02381730 · Fondation Ophtalmologique Adolphe de Rothschild
2014-01 – 2017-08-31 · Polypoidal Choroidal Vasculopathy
What this study did
NCT03712670 · Università degli Studi di Brescia
2016-01-01 – 2017-03-15 · Retinal Disease
What this study did
NCT01711879 · University of Colorado, Denver
2013-01 – 2015-10 · Neovascular Glaucoma
What this study did
NCT01965041 · Manhattan Eye, Ear & Throat Hospital
2013-10 – 2014-11 · Pattern Dystrophy of Macula
What this study did
NCT01941173 · City of Hope Medical Center
2014-01 – 2014-07 · Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
What this study did
Used as active comparator (109)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (63)
Age-Related Macular Degeneration
NCT06864988 · 4D Molecular Therapeutics
2025-03-03 – 2028-06 · Macular Neovascularization Secondary to Age-Related Macular Degeneration
What this study did
NCT04005352 · Novartis Pharmaceuticals
2019-09-25 – 2022-09-09 · Age-related Macular Degeneration
What this study did
NCT03710564 · Novartis Pharmaceuticals
2018-10-30 – 2021-07-01 · Age-Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT07867080 · 4D Molecular Therapeutics
2026-09-18 – 2030-01 · Diabetic Macular Edema (DME)
What this study did
NCT07842016 · Ollin Biosciences, Inc.
2026-10-15 – 2029-12-15 · Diabetic Macular Edema (DME)
What this study did
NCT07841899 · Ollin Biosciences, Inc.
2026-10-15 – 2029-12-15 · Diabetic Macular Edema (DME)
What this study did
NCT07705607 · Merck Sharp & Dohme LLC
2026-09-25 – 2029-11-30 · Diabetic Retinopathy, Macular Edema
What this study did
NCT07705555 · Merck Sharp & Dohme LLC
2026-08-27 – 2029-10-31 · Diabetic Retinopathy, Macular Edema
What this study did
NCT07734844 · Kodiak Sciences Inc
2026-08-03 – 2029-09 · Diabetic Macular Edema (DME)
What this study did
NCT07449923 · EyePoint Pharmaceuticals, Inc.
2026-02-09 – 2028-10 · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
What this study did
NCT07449936 · EyePoint Pharmaceuticals, Inc.
2026-02-16 – 2028-10 · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
What this study did
NCT07489131 · Alvotech Swiss AG
2026-04-22 – 2028-01 · Diabetic Macular Edema
What this study did
NCT05885503 · RemeGen Co., Ltd.
2023-06-08 – 2026-06 · Diabetic Macular Edema
What this study did
NCT05324774 · Mabwell (Shanghai) Bioscience Co., Ltd.
2022-02-28 – 2024-07-30 · Diabetic Macular Edema
What this study did
NCT04603937 · Kodiak Sciences Inc
2020-09-30 – 2023-08-31 · Diabetic Macular Edema
What this study did
NCT04611152 · Kodiak Sciences Inc
2020-09-30 – 2023-08-31 · Diabetic Macular Edema
What this study did
NCT03622593 · Hoffmann-La Roche
2018-10-09 – 2023-05-31 · Diabetic Macular Edema
What this study did
NCT04739306 · Celltrion
2021-07-22 – 2023-04-24 · Diabetic Macular Edema (DME)
What this study did
NCT04079231 · Novartis Pharmaceuticals
2021-02-01 – 2023-01-31 · Diabetic Macula Edema
What this study did
NCT04058067 · Novartis Pharmaceuticals
2019-08-23 – 2023-01-31 · Diabetic Macular Edema
What this study did
NCT03481634 · Novartis Pharmaceuticals
2018-07-23 – 2021-10-18 · Diabetic Macular Edema
What this study did
NCT03610646 · Mylan Pharmaceuticals Inc
2018-08-23 – 2021-09-10 · Diabetic Macular Edema
What this study did
NCT03622580 · Hoffmann-La Roche
2018-09-05 – 2021-09-03 · Diabetic Macular Edema
What this study did
NCT03481660 · Novartis Pharmaceuticals
2018-07-27 – 2021-06-08 · Diabetic Macular Edema
What this study did
NCT03917472 · Novartis Pharmaceuticals
2019-07-17 – 2021-03-24 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT07317934 · Innostellar Biotherapeutics Co.,Ltd
2026-01-14 – 2032-06-04 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
What this study did
NCT07482176 · Adverum Biotechnologies, Inc.
2026-03-16 – 2031-10-20 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
What this study did
NCT06856577 · Adverum Biotechnologies, Inc.
2025-02-28 – 2030-11-23 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
What this study did
NCT07816315 · Ollin Biosciences, Inc.
2026-10-15 – 2029-12-15 · Wet Age Related Macular Degeneration
What this study did
NCT07064759 · 4D Molecular Therapeutics
2025-07-22 – 2029-11 · Neovascular Age-Related Macular Degeneration (nAMD)
What this study did
NCT07614776 · Amgen
2026-05-27 – 2028-01-12 · Neovascular Age-related Macular Degeneration, nAMD
What this study did
NCT05407636 · AbbVie
2022-01-13 – 2027-11 · AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
What this study did
NCT07489586 · Qilu Pharmaceutical Co., Ltd.
2026-03 – 2027-08 · Neovascular Age-Related Macular Degeneration (nAMD)
What this study did
NCT06556368 · Kodiak Sciences Inc
2024-08-23 – 2027-08 · Wet Age-related Macular Degeneration
What this study did
NCT05972473 · Innovent Biologics (Suzhou) Co. Ltd.
2023-09-21 – 2027-04-30 · Neovascular Age-related Macular Degeneration
What this study did
NCT06668064 · EyePoint Pharmaceuticals, Inc.
2024-10-22 – 2027-03 · Wet Age Related Macular Degeneration, wAMD
What this study did
NCT06683742 · EyePoint Pharmaceuticals, Inc.
2024-11-27 – 2027-03 · Wet Age Related Macular Degeneration, wAMD
What this study did
NCT06495918 · Ocular Therapeutix, Inc.
2024-11-27 – 2027-01-08 · Neovascular Age-related Macular Degeneration
What this study did
NCT06470373 · Rophibio, Inc.
2025-07 – 2026-09 · Neovascular Age-related Macular Degeneration (nAMD)
What this study did
NCT05727397 · RemeGen Co., Ltd.
2023-03-14 – 2025-12-29 · Wet Age-related Macular Degeneration
What this study did
NCT04047472 · Novartis Pharmaceuticals
2019-11-29 – 2024-02-28 · Neovascular Age-Related Macular Degeneration
What this study did
NCT04572698 · Luye Pharma Group Ltd.
2020-11 – 2023-12 · Age Related Macular Degeneration
What this study did
NCT04522167 · Bioeq GmbH
2020-07-21 – 2023-05-18 · Neovascular Age-related Macular Degeneration
What this study did
NCT04864834 · Sandoz
2021-05-12 – 2023-05-10 · Neovascular Age-related Macular Degeneration
What this study did
NCT04964089 · Kodiak Sciences Inc
2021-06-23 – 2023-04-06 · Wet Age-related Macular Degeneration
What this study did
NCT04270747 · Amgen
2020-06-22 – 2023-01-30 · Neovascular (Wet) Age-related Macular Degeneration (AMD)
What this study did
NCT04480463 · Sam Chun Dang Pharm. Co. Ltd.
2020-08-13 – 2022-09-08 · Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
What this study did
NCT05587062 · Cinnagen
2019-10-01 – 2022-07-31 · Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration
What this study did
Phase 2/3 (4)
Age-Related Macular Degeneration
NCT07496567 · EyeBiotech Ltd.
2026-04-15 – 2028-07-31 · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
What this study did
NCT07440225 · EyeBiotech Ltd.
2026-03-27 – 2028-06-30 · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
What this study did
Diabetic Macular Edema
NCT04429503 · Regeneron Pharmaceuticals
2020-06-29 – 2024-06-18 · Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
What this study did
Wet Age-Related Macular Degeneration
Phase 2 (22)
Age-Related Macular Degeneration
NCT02357342 · Maturi, Raj K., M.D., P.C.
2015-04 – 2017-01 · Age-Related Macular Degeneration
What this study did
NCT01796964 · Alcon Research
2013-03 – 2014-08 · Exudative Age-Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT05930561 · 4D Molecular Therapeutics
2023-08-09 – 2029-02-28 · Diabetic Macular Edema, Diabetic Retinopathy
What this study did
NCT06942520 · Sierra Eye Associates
2025-03-18 – 2027-12 · Diabetic Macular Edema
What this study did
NCT04567550 · AbbVie
2020-11-20 – 2026-06-18 · Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
What this study did
NCT06099184 · EyePoint Pharmaceuticals, Inc.
2024-01-15 – 2024-10-24 · Diabetic Macular Edema
What this study did
NCT04527107 · Oxurion
2020-07-31 – 2023-11-22 · Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
What this study did
NCT05063734 · Oxurion
2021-08-27 – 2022-06-29 · Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT07776522 · West China Hospital
2026-08-31 – 2032-01-14 · Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
What this study did
NCT06196840 · Innostellar Biotherapeutics Co.,Ltd
2024-01-24 – 2029-10 · Neovascular Age-Related Macular Degeneration
What this study did
NCT07798375 · Everest Medicines (China) Co.,Ltd.
2026-11 – 2028-12 · Neovascular Age Related Macular Degeneration(nAMD)
What this study did
NCT07557121 · AiViva BioPharma, Inc.
2026-07-01 – 2027-08-23 · Neovascular (Wet) Age-Related Macular Degeneration
What this study did
The Sahlgrenska Anti-VEGF Studyactive not recruiting
NCT04101877 · Vastra Gotaland Region
2020-09-03 – 2027-05 · Neovascular Age-related Macular Degeneration
What this study did
NCT06839339 · Beijing Anlong Biopharmaceutical Co., Ltd.
2025-02-18 – 2027-01-30 · Wet Age-related Macular Degeneration (wAMD)
What this study did
NCT05891548 · Clearside Biomedical, Inc.
2023-05-31 – 2024-08-20 · Neovascular Age-related Macular Degeneration
What this study did
NCT05403749 · Innovent Biologics (Suzhou) Co. Ltd.
2022-06-29 – 2024-05-13 · Neovascular Age-related Macular Degeneration
What this study did
NCT05381948 · EyePoint Pharmaceuticals, Inc.
2022-06-30 – 2024-04-24 · Wet Age-related Macular Degeneration
What this study did
NCT05275205 · Unity Biotechnology, Inc.
2022-03-02 – 2023-07-25 · Neovascular Age-related Macular Degeneration
What this study did
NCT04820452 · Innovent Biologics (Suzhou) Co. Ltd.
2021-04-28 – 2023-01-13 · Neovascular Age-related Macular Degeneration
What this study did
NCT03953079 · Graybug Vision
2019-09-26 – 2021-06-03 · Neovascular Age-Related Macular Degeneration
What this study did
Other / comorbidity
NCT06321302 · Boehringer Ingelheim
2024-05-15 – 2027-08-20 · Diabetic Retinopathy
What this study did
NCT03186326 · Federation Francophone de Cancerologie Digestive
2018-04-24 – 2025-03-01 · Metastatic Colorectal Cancer, MSI
What this study did
Phase 1/2 (5)
Age-Related Macular Degeneration
Wet Age-Related Macular Degeneration
NCT05197270 · 4D Molecular Therapeutics
2021-12-09 – 2031-01 · Neovascular (Wet) Age-Related Macular Degeneration
What this study did
NCT05769153 · Alcon Research
2023-12-06 – 2027-09 · Neovascular Age-related Macular Degeneration (nAMD)
What this study did
NCT05961007 · Innovent Biologics (Suzhou) Co. Ltd.
2021-11-18 – 2024-04-30 · Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
What this study did
Other / comorbidity
NCT06672536 · Sinocelltech Ltd.
2024-11-26 – 2027-01-11 · nAMD
What this study did
Phase 1 (6)
Age-Related Macular Degeneration
NCT06132035 · Caregen Co. Ltd.
2023-12-22 – 2025-08 · Age-related Wet Macular Degeneration
What this study did
Diabetic Macular Edema
NCT05324592 · Mabwell (Shanghai) Bioscience Co., Ltd.
2021-02-26 – 2022-01-25 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT04919096 · Clover Biopharmaceuticals AUS Pty
2022-04 – 2023-01 · Wet Age-related Macular Degeneration
What this study did
NCT04370379 · Innovent Biologics (Suzhou) Co. Ltd.
2020-05-28 – 2021-05-08 · Neovascular Age-related Macular Degeneration
What this study did
NCT04058535 · Alteogen, Inc.
2020-02-05 – 2020-12-22 · Neovascular Age-related Macular Degeneration
What this study did
NCT03249740 · Graybug Vision
2017-08-29 – 2019-01-16 · Neovascular Age-Related Macular Degeneration
What this study did
Phase 4 (8)
Age-Related Macular Degeneration
NCT04698850 · Faculty Hospital Kralovske Vinohrady
2021-01-04 – 2023-06 · Wet Macular Degeneration
What this study did
NCT02130024 · Novartis Pharmaceuticals
2014-04-11 – 2017-11-15 · Age-Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT05990829 · Tianjin Medical University Eye Hospital
2023-10-01 – 2025-04-01 · Diabetic Macular Edema, Pars Plana Vitrectomy, Dexamethasone Intravitreal Implant, Intraoperative Optical Coherence Tomography
What this study did
NCT03832179 · Bay Area Retina Associates
2018-11-15 – 2024-03-30 · Diabetic Macular Edema, Cataract
What this study did
Wet Age-Related Macular Degeneration
NCT05941715 · Medical University of Graz
2023-07-04 – 2025-02-26 · Neovascular Age-related Macular Degeneration
What this study did
NCT05710471 · The University of Hong Kong
2022-07-25 – 2023-08-30 · Age-Related Macular Degeneration
What this study did
NCT01958918 · Novartis Pharmaceuticals
2013-10-23 – 2017-05-29 · Neovascular Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT03999125 · Sudhalkar Eye Hospital
2019-06-25 – 2023-06-24 · Clinically Significant Macular Edema Due to Diabetes Mellitus
What this study did
Early phase / not applicable (1)
Diabetic Macular Edema
NCT07096713 · Benha University
2024-01-01 – 2024-06-01 · Anti-VEGF Therapy
What this study did
Appears in other studies (27)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (6)
Age-Related Macular Degeneration
NCT05251636 · Salutaris Medical Devices, Inc.
2025-03 – 2028-09 · Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy
What this study did
NCT01940887 · Ophthotech Corporation
2014-05 – 2017-09 · Age-Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT04674800 · Mylan Pharmaceuticals Inc
2020-11-23 – 2022-04-20 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT04663750 · King's College Hospital NHS Trust
2021-04-16 – 2028-12 · Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage
What this study did
NCT06491914 · Regeneron Pharmaceuticals
2024-07-24 – 2027-01-07 · Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
What this study did
Other / comorbidity
NCT07389980 · Yeungnam University College of Medicine
2026-12-24 – 2028-12 · Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
What this study did
Phase 2 (12)
Age-Related Macular Degeneration
NCT02348359 · Tyrogenex
2015-03-16 – 2018-01-12 · Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD, Macular Degeneration, Age-related, 10, Eye Diseases, Retinal Degeneration, Retinal Diseases
What this study did
NCT02732899 · Maturi, Raj K., M.D., P.C.
2016-04 – 2017-04-04 · Exudative Age Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT06116916 · Kyowa Kirin Co., Ltd.
2024-01-09 – 2026-11-30 · Diabetic Macular Edema (DME)
What this study did
NCT06845163 · Alexandria University
2025-02-08 – 2026-07-14 · Diabetic Macular Edema, Center-involved Diabetic Macular Edema
What this study did
NCT06011798 · Unity Biotechnology, Inc.
2023-08-23 – 2025-04-08 · Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
What this study did
Wet Age-Related Macular Degeneration
NCT07205887 · EyeBiotech Ltd.
2025-09-12 – 2028-06-30 · Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
What this study did
NCT07844343 · Samsung Bioepis Co., Ltd.
2026-09-07 – 2026-09-22 · Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
What this study did
NCT06116890 · Kyowa Kirin Co., Ltd.
2024-01-31 – 2026-07-01 · Neovascular Age-Related Macular Degeneration (nAMD)
What this study did
NCT04684394 · Gemini Therapeutics, Inc.
2020-12-29 – 2022-02-18 · Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration
What this study did
NCT04331730 · Alkahest, Inc.
2020-01-28 – 2021-09-16 · Neovascular Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT05296447 · AbbVie
2022-04-04 – 2031-06 · Diabetic Retinopathy, DR
What this study did
NCT06121180 · H. Lee Moffitt Cancer Center and Research Institute
2024-11-04 – 2030-10-31 · Metastatic Uveal Melanoma
What this study did
Phase 1/2 (1)
Diabetic Macular Edema
NCT03397264 · Opthea Limited
2018-01-16 – 2020-06-11 · Diabetic Macular Edema
What this study did
Phase 1 (3)
Diabetic Macular Edema
NCT06879301 · Tanta University
2025-03-19 – 2026-07-19 · Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation
What this study did
Wet Age-Related Macular Degeneration
NCT06817343 · Exegenesis Bio
2024-09-10 – 2029-02 · Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
What this study did
NCT07728981 · Tianjin Medical University Eye Hospital
2026-07-25 – 2027-12-31 · Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
What this study did
Phase 4 (4)
Diabetic Macular Edema
NCT06662994 · Retina Consultants of Orange County
2025-07-07 – 2027-08-15 · Diabetic Macular Edema (DME)
What this study did
NCT03984110 · Texas Retina Associates
2019-06-11 – 2022-10-27 · Diabetic Macular Edema
What this study did
Other / comorbidity
NCT07118670 · Edward Wood, MD
2025-12-08 – 2028-04 · Proliferative Diabetic Retinopathy (PDR)
What this study did
NCT02432547 · University of Sydney
2017-06-15 – 2022-05-24 · Diabetic Retinopathy
What this study did
Early phase / not applicable (1)
Diabetic Macular Edema
NCT06610747 · Zhongshan Ophthalmic Center, Sun Yat-sen University
2024-10-28 – 2027-04-30 · Diabetic Macular Edema
What this study did

Competitive landscape

This mechanism is crowded: 38 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Age-Related Macular Degeneration: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Aflibercept (Eylea): this drugApprovedProtein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Reliable signal
NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0)
NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42%
Aflibercept-Abzv (Enzeevu)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)ApprovedProtein / enzyme therapeuticVEGF-AReliable signal
NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97)
Aflibercept-Boav (Eydenzelt)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Avacincaptad Pegol (Izervay)ApprovedRNA AptamerComplement C5Reliable signal
NCT04435366: 12-month geographic-atrophy growth: 0.336 vs 0.392 mm/year for avacincaptad pegol vs sham; difference 0.056 mm/year (95% CI 0.016 to 0.096; p=0.0064). 24-month geographic-atrophy growth: 2.23 vs 2.59 mm²/year for monthly avacincaptad pegol vs sham; difference 0.362 mm²/year (95% CI 0.066 to 0.657; p=0.0165).
NCT02686658: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence (Baseline and 12 months): Zimura 2 mg [Part 1 & Part 2 Combined] 0.292 millimeters (mm) (Standard Error 0.077) | Zimura 4 mg [Part 2] 0.321 millimeters (mm) (Standard Error 0.074) vs Sham [Part 1 & Part 2 Combined] 0.402 millimeters (mm) (Standard Error 0.075) | Sham [Part 2] 0.444 millimeters (mm) (Standard Error 0.072)
BAT1706 (Avzivi)
Approved(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Bevacizumab
Approved(overall)
Monoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitor
Partial signal(overall)
No reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)
Approved(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Brolucizumab-DbllApprovedAntibody fragmentVEGF-AWeak signalNo reviewed efficacy summary in this indication
FaricimabApprovedMultispecific antibodyAngiopoietin-2 / VEGF-APartial signal
NCT03823287: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 5.8 vs 5.1 letters, adjusted mean difference 0.7 (95% CI -1.1 to 2.5); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
NCT03823300: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 6.6 vs 6.6 letters, adjusted mean difference 0.0 (95% CI -1.7 to 1.8); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
Jobevne (bevacizumab-Nwgd)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Pegcetacoplan Ophthalmic (Syfovre)ApprovedPeptideComplement C3, Complement C3 / C3bReliable signal
NCT03525613: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218)
NCT03525600: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) missed
Ranibizumab (Lucentis)ApprovedAntibody fragmentVEGF-APartial signal
NCT00056836: Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.
Ranibizumab-Eqrn (Cimerli)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Vegzelma (bevacizumab-Adcd)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Verteporfin (Visudyne)ApprovedSmall moleculeBenzoporphyrin-derivative photosensitizer for photodynamic therapyPartial signal
NCT00436553: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 (Baseline and Month 12): Verteporfin SF + Ranibizumab — Baseline: 53.7 Letters (Standard Deviation 13.52); Month 12: 59 Letters (Standard Deviation 17.47); Change from baseline: 5.3 Letters (Standard Deviation 15.66) | Verteporfin RF + Ranibizumab — Baseline: 54.6 Letters (Standard Deviation 12.78); Month 12: 59 Letters (Standard Deviation 18.03); Change from baseline: 4.4 Letters (Standard Deviation 15.47) vs Ranibizumab Monotherapy — Baseline: 54.8 Letters (Standard Deviation 13.55); Month 12: 63 Letters (Standard Deviation 18.88); Change from baseline: 8.1 Letters (Standard Deviation 15.09) missed
NCT00121407: VIO trial, 24-month primary endpoint: 47% of verteporfin-PDT patients vs 53% of placebo patients lost ≥15 letters (not significant); source states n=384 vs task record's 364, but sponsor/design/QLT-era details match this trial (2:1 randomization, occult CNV, no classic component). missed
Zirabev (bevacizumab-Bvzr)
Approved(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Axitinib Intravitreal Implant (OTX-TKI)Phase 3Small moleculeVEGF receptors + PDGF receptorsPartial signal
NCT06223958: Superiority primary endpoint at week 36: 74.1% with AXPAXLI vs 55.8% with aflibercept 2 mg lost fewer than 15 ETDRS letters (2026-02-17).
BAT5906Phase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
CKD-701 (Lucenbies)Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT04857177: Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%).
HD204
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
HLX04 (Hanbeitai)
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
HLX04-OPhase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
IBI305
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
LY01008
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ximluci)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RC28-EPhase 3Protein / enzyme therapeuticVEGF-A / FGF-2 (dual blockade)Partial signal
NCT04270669: Mean BCVA improvement from baseline at week 48: 6.1 ± 8.3 letters (0.5 mg), 9.9 ± 10.7 letters (1.0 mg), 7.6 ± 9.4 letters (2.0 mg)
Surabgene LomparvovecPhase 3Gene therapy / editingVEGF-AWeak signal
NCT04832724: Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0
Tabirafusp TedromerPhase 3Multispecific antibodyVEGF + IL-6Partial signal
NCT06556368: Primary endpoint: tabirafusp tedromer non-inferior to aflibercept on vision (p=0.0036); anatomical key secondary endpoint p<0.0001 (DAYBREAK, 2026-09-28).
Tarcocimab TedromerPhase 3Monoclonal antibodyVEGF-APartial signal
NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76)
NCT06556368: Primary endpoint, BCVA: met (p=0.0007) (Kodiak topline, 2026-09-28).
VonaprumentPhase 3Antibody fragmentComplement C1qPartial signal
NCT04656561: GA lesion growth vs sham at 12 months: 6.2% reduction monthly (p=0.526), 1.3% every-other-month (p=0.896), 3.7% pooled (p=0.673); primary endpoint not statistically significant. missed
MW02Phase 2/3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
BI 1584862Phase 2——not yet gradedNo reviewed efficacy summary in this indication
BI 771716Phase 2Antibody fragment—Weak signalFeatured results are safety only in this race
Iptacopan (Fabhalta)Phase 2Small moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
ABBV-6628Phase 1/2Antibody fragmentComplement C5not yet gradedNo reviewed efficacy summary in this indication
SAR402663Phase 1/2Gene therapy / editingVEGFnot yet gradedNo reviewed efficacy summary in this indication
SAR446597Phase 1/2Gene therapy / editingComplement C1s + Factor Bbnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LazucirnonDiscontinuedSmall moleculeCCR3Partial signal
NCT04331730: Mean change in BCVA (ETDRS letters) from baseline to Week 36: AKST4290 800 mg + aflibercept +10.4 (SD 10.26, n=36), AKST4290 1600 mg + aflibercept +6.7 (SD 7.89, n=35), placebo + aflibercept +13.7 (SD 7.60, n=36); no between-group analysis posted (CT.gov posted results).
Telbermin
Discontinued
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Eylea (Aflibercept) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
June 2027 (1)
Early phase / not applicableAge-Related Macular DegenerationActive not recruiting
Est. primary completion 2027-06 · NCT04932980 · CT.gov ↗
What to watch
September 2027 (2)
Early phase / not applicableDiabetic Macular EdemaActive not recruiting
Est. primary completion 2027-09 · NCT02645266 · CT.gov ↗
What to watch
Phase 4Diabetic Macular EdemaNot yet recruiting
Est. primary completion 2027-09-15 · NCT07438119 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Age-Related Macular DegenerationNot yet recruiting
Est. primary completion 2027-12-31 · NCT07365371 · CT.gov ↗
What to watch
2028 (3)
June 2028 (2)
Phase 2GlaucomaNot yet recruiting
Est. primary completion 2028-06 · NCT07891182 · CT.gov ↗
What to watch
Phase 4Diabetic Macular EdemaNot yet recruiting
Est. primary completion 2028-06-30 · NCT07612904 · CT.gov ↗
What to watch
September 2028 (1)
Phase 4Age-Related Macular DegenerationNot yet recruiting
Est. primary completion 2028-09-30 · NCT07940998 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 April 2026ApprovalFDA approves EYLEA HD dosing intervals up to every 20 weeks
US, FDA · Source ↗
April 2026FDA action dateFDA target action date for EYLEA HD prefilled syringe
US, FDA · Source ↗
16 January 2026ApprovalEylea 8 mg approved in the EU for macular edema following RVO
EU, EMA · Source ↗